Is compounded semaglutide safe?

The honest answer is that nobody can tell you, because the studies that would answer it have not been done. What can be said is narrower and more useful: compounded semaglutide is not reviewed by the FDA before it reaches you, the agency has documented specific problems with it, and the one comparison study that exists did not favour it.

That is different from saying it is dangerous. Plenty of people have taken compounded semaglutide without incident. But "no reported problem" is not the same as "verified safe," and the gap between those two things is what this page is about.

What "not FDA approved" actually means

When a drug is approved, the manufacturer has to show the FDA evidence from clinical trials that it works and that its risks are understood, and the FDA inspects how it is made. None of that happens with a compounded product. The pharmacy is licensed. The specific medicine in the vial is not reviewed.

This is normal for compounding, and compounding has legitimate uses. It becomes a bigger question when a compounded product is produced at scale and marketed to thousands of people who could take the approved version instead.

What the FDA has documented

These are the agency's own stated concerns, not our interpretation.

Dosing errors. The FDA has received multiple adverse event reports, some involving hospitalisation, connected to dosing errors with compounded injectable semaglutide. Two patterns come up. Patients measuring their own dose from a vial and syringe rather than a pre-filled pen, and patients being prescribed doses beyond the approved label through larger single doses, more frequent dosing, or faster increases than the approved schedule uses.

A different active ingredient in some products. Some products sold as semaglutide have used salt forms, semaglutide sodium or semaglutide acetate. The FDA has said these are different active ingredients from the one used in the approved drugs.

Ingredient quality. The FDA put an import alert in place to stop GLP-1 raw ingredients with potential quality problems from entering the country.

Temperature. These are refrigerated medicines. The agency has received complaints of product arriving warm, or with too little ice to hold it at the right temperature in transit.

Counterfeits and false labelling, including product carrying false information on the label.

The reported total. As of 31 May 2026, the FDA had received 990 adverse event reports relating to compounded semaglutide.

The number people quote wrongly

You will see a figure claiming that compounded products have dramatically higher rates of preparation errors and contamination. It comes from an analysis of the FDA's adverse event reporting database.

That database is voluntary. Anyone can file a report, nobody has to, and the number of reports tells you nothing about how many people took the drug. What the analysis produces is a reporting odds ratio, which can show that a signal exists. It cannot tell you how often something happens and it cannot establish that the drug caused it.

So the honest version is: the signal is real and worth knowing about, and anyone quoting it as a rate is overstating it. We are not going to do that, and you should be careful with any page that does.

What about the products that are fine?

Most compounded semaglutide is presumably made competently by licensed pharmacies. The problem is that you cannot tell from the outside which is which, and the usual signals people rely on do not work here. A professional website is not evidence. A doctor's involvement is not evidence about the pharmacy. The FDA has been explicit that compounding facilities "are not 'FDA-approved' or 'FDA-licensed' entities," so a company describing its source that way is telling you something, just not what it intended.

What actually changed in 2025

Large scale compounding of semaglutide was permitted because the approved product was in shortage. The FDA determined that shortage was resolved on 21 February 2025, and the enforcement discretion ended on 22 April 2025 for state licensed pharmacies and 22 May 2025 for outsourcing facilities.

That matters for safety in an indirect but real way. Product still being sold after those dates is being sold under a narrower legal argument about personalisation, and it is worth asking a provider to explain theirs.

What to ask

• Is this FDA approved, or is it compounded?
• Which pharmacy or outsourcing facility makes it, and are they registered with the FDA?
• Is the active ingredient semaglutide, or a salt form such as semaglutide sodium or acetate?
• Am I measuring my own dose, or is it pre-filled?
• Does my dosing schedule match the approved product's schedule, and if not, why not?
• How is it shipped, and what should I do if it arrives warm?

Sources

• FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss"
• FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize"
• FDA, "FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs"
• Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety, 2025. doi:10.1080/14740338.2025.2499670
• Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Annals of Pharmacotherapy, 2026. doi:10.1177/10600280261421979

How we verify: see /how-we-verify.

Keep reading

Does compounded semaglutide work as well as the approved version? The one head to head comparison, at /guides/does-compounded-semaglutide-work.

How to check whether a provider is legitimate, at /guides/how-to-check-a-telehealth-provider.